Related references
Note: Only part of the references are listed.Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling
Taku Shigesawa et al.
CARCINOGENESIS (2021)
Three-Dimensional Primary Cell Culture: A Novel Preclinical Model for Pancreatic Neuroendocrine Tumors
Simon Leonhard April-Monn et al.
NEUROENDOCRINOLOGY (2021)
Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma
Chung-Han Lee et al.
BRITISH JOURNAL OF CANCER (2021)
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)
Jaume Capdevila et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?
Satya Das et al.
CURRENT ONCOLOGY REPORTS (2021)
The 2019 WHO classification of tumours of the digestive system
Iris D. Nagtegaal et al.
HISTOPATHOLOGY (2020)
Neuroendocrine Tumors-Less Well Known, Often Misunderstood, and Rapidly Growing in Incidence
Aman Chauhan et al.
JAMA ONCOLOGY (2020)
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
Matthew H. Taylor et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase-II Trials of Pazopanib in Metastatic Neuroendocrine Neoplasia (mNEN): A Systematic Review and Meta-Analysis
Alberto Bongiovanni et al.
FRONTIERS IN ONCOLOGY (2020)
Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy
Yan Zhao et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2020)
Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma
Masami Yamauchi et al.
Clinical and Translational Gastroenterology (2020)
Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial
Jun Sato et al.
LANCET ONCOLOGY (2020)
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study
Jianming Xu et al.
LANCET ONCOLOGY (2020)
Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy
L. D. Locati et al.
EUROPEAN JOURNAL OF CANCER (2019)
Pan-cancer whole-genome analyses of metastatic solid tumours
Peter Priestley et al.
NATURE (2019)
Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives
Aura D. Herrera-Martinez et al.
DRUGS (2019)
Management of Gastrointestinal Neuroendocrine Tumors
Rongzhi Wang et al.
CLINICAL MEDICINE INSIGHTS-ENDOCRINOLOGY AND DIABETES (2019)
Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets
E. T. Aristizabal Prada et al.
ENDOCRINE CONNECTIONS (2018)
Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models
Kenta Kawasaki et al.
DISEASE MODELS & MECHANISMS (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Daniel Benten et al.
MOLECULAR CANCER RESEARCH (2018)
Treatment options for PNET liver metastases: a systematic review
Giuseppe Nigri et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2018)
Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models
Masahiro Matsuki et al.
CANCER MEDICINE (2018)
Gastroenteropancreatic Neuroendocrine Tumors
Mauro Cives et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration
Silvia Martina Ferrari et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid
Makoto Tahara et al.
EUROPEAN JOURNAL OF CANCER (2017)
Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine
Chantal Pauli et al.
CANCER DISCOVERY (2017)
Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care
David P. Kodack et al.
CELL REPORTS (2017)
Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas
Bryan Oronsky et al.
NEOPLASIA (2017)
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
Arvind Dasari et al.
JAMA ONCOLOGY (2017)
Identifying and Prioritizing Gaps in Neuroendocrine Tumor Research: A Modified Delphi Process With Patients and Health Care Providers to Set the Research Action Plan for the Newly Formed Commonwealth Neuroendocrine Tumor Collaboration
Eva Segelov et al.
JOURNAL OF GLOBAL ONCOLOGY (2017)
Novel treatment options for anaplastic thyroid cancer
Poupak Fallahi et al.
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM (2017)
A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
Martin Schlumberger et al.
CLINICAL CANCER RESEARCH (2016)
Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors
Dik J. Kwekkeboom et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2016)
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
Marc van de Wetering et al.
CELL (2015)
Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects
Anna Koumarianou et al.
NEUROENDOCRINOLOGY (2015)
First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma
Alberto Bongiovanni et al.
ONCOTARGETS AND THERAPY (2015)
Pharmacokinetics and excretion of 14C-lenvatinib in patients with advanced solid tumors or lymphomas
Anne-Charlotte Dubbelman et al.
INVESTIGATIONAL NEW DRUGS (2015)
Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
Osamu Tohyama et al.
JOURNAL OF THYROID RESEARCH (2014)
Angiogenesis in Neuroendocrine Tumors: Therapeutic Applications
Jean-Yves Scoazec
NEUROENDOCRINOLOGY (2013)
Gastroenteropancreatic neuroendocrine tumours
Irvin M. Modlin et al.
LANCET ONCOLOGY (2008)
Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors
Wandena S. Siegel-Lakhai et al.
CLINICAL CANCER RESEARCH (2007)
Clinical pharmacokinetics of everolimus
GI Kirchner et al.
CLINICAL PHARMACOKINETICS (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
